Insider Selling: GoodRx (NASDAQ:GDRX) Major Shareholder Sells $961,509.50 in Stock

Key Points

• Francisco Partners sold 274,717 GoodRx shares at an average price of $3.50, generating $961,509.50 and reducing its ownership by 26.12% to 777,213 shares. The shareholder also sold more than 919,000 shares in two transactions earlier in the week.
• GoodRx shares fell 3.1% to $3.45, though the stock remained above its 50-day and 200-day moving averages. The company has a $1.18 billion market capitalization and trades at a high price-to-earnings ratio of 86.27.
• GoodRx reported quarterly revenue of $200.41 million and adjusted earnings of $0.08 per share, matching analyst expectations, but revenue declined 1.3% year over year. Analysts maintain a consensus “Hold” rating with an average price target of $4.23.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.50, for a total transaction of $961,509.50. Following the sale, the insider owned 777,213 shares in the company, valued at approximately $2,720,245.50. This represents a 26.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total transaction of $1,666,071.75.

GoodRx Trading Down 3.1%

Shares of GDRX stock traded down $0.11 during trading hours on Friday, hitting $3.45. 1,746,243 shares of the company's stock traded hands, compared to its average volume of 1,833,117. The stock's 50 day simple moving average is $3.13 and its 200 day simple moving average is $2.63. The stock has a market cap of $1.18 billion, a PE ratio of 86.27, a price-to-earnings-growth ratio of 1.77 and a beta of 1.60. GoodRx Holdings, Inc. has a 12 month low of $1.77 and a 12 month high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts' consensus estimates of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. During the same quarter in the previous year, the business earned $0.09 earnings per share. GoodRx's revenue was down 1.3% compared to the same quarter last year. On average, sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Institutional Trading of GoodRx

A number of large investors have recently bought and sold shares of GDRX. AQR Capital Management LLC raised its position in shares of GoodRx by 124.4% in the 1st quarter. AQR Capital Management LLC now owns 282,320 shares of the company's stock worth $1,245,000 after acquiring an additional 156,482 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of GoodRx by 7.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company's stock valued at $3,455,000 after purchasing an additional 54,783 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of GoodRx during the 1st quarter valued at about $370,000. Creative Planning bought a new stake in shares of GoodRx during the 2nd quarter valued at about $93,000. Finally, Cetera Investment Advisers acquired a new stake in GoodRx during the second quarter worth approximately $50,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GDRX has been the topic of a number of analyst reports. UBS Group upped their price target on GoodRx from $2.50 to $3.75 and gave the company a "neutral" rating in a research report on Thursday, August 13th. Weiss Ratings upgraded GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, August 7th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $4.00 price objective on shares of GoodRx in a research note on Friday, August 7th. TD Cowen upped their target price on GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Finally, Barclays increased their target price on shares of GoodRx from $3.00 to $4.00 and gave the company an "underweight" rating in a research report on Thursday. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, GoodRx presently has an average rating of "Hold" and a consensus price target of $4.23.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source